NEUROCHEMICAL JOURNAL, cilt.19, sa.2, ss.179-184, 2025 (SCI-Expanded)
Doxorubicin (DOX), a chemotherapeutic medicine, are frequently utilized to treat various malignancies,
even though it has well-documented negative side effects. Neurotoxic effect is one of the best known
and occurs through several mechanisms including oxidative stress and neuro-inflammation. Transcranial
direct current stimulation (tDCS), a non-invasive brain stimulation technique, is used in several neurodegenerative
disease model because of its neuroprotective effects. The aim of this study was to investigate the effects
of DOX on antioxidant and inflammatory markers, behavioral parameters and the possible neuroprotective
effect of tDCS stimulation on these effects. To induce neurotoxicity, DOX was administered intraperitoneally
(i.p.) at 2.15 mg/kg/day, 1 dose in 3 days, 7 times in total for 3 weeks. tDCS treatment was then applied for 5
consecutive days. Catalase (CAT), interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and
interleukin 6 (IL-6) levels were evaluated. Open field test was used to analyzed to locomotor activity and
behavioral changes. The DOX group had neuronal alteration as indicated by the elevation of neuro-inflammation
markers (IL-1β, TNF-α, and IL-6) with reduced antioxidant marker (CAT). The tDCS-treated
group showed a significant reduction in the inflammation biomarkers, with a significant improvement in the
antioxidant marker. DOX administration impaired locomotor activity as well as anxiety behaviors of rats.
tDCS have also been shown to be effective in preventing behavioral and locomotor changes; therefore, they
may be considered as candidates to reduce toxicity effects in DOX treatments. Our findings reveal the importance
of tDCS treatment to attenuate DOX-associated neurotoxicity. Through the modification and decrease
of indicators of cellular toxicity and the increase of natural antioxidant enzymes, tDCS demonstrated considerable
promise for avoiding DOX-induced neurotoxicity.